Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial

Phase 3 Completed 82 enrolled Shahid Beheshti University of Medical Sciences

RandomizedParallel-groupDouble-blindTreatment

Summary

In this study we intend to evaluate the outcome of intravitreal avastin on improving the visual acuity and macular edema and late complications of BRVO like NVD and NVE

Timeline

Start: 2006-08
Primary completion: 2008-02
Completion: 2008-06

Outcome

Mixed primary results

paper In acute BRVO, two IVB injections resulted in significant improvement of vision and CMT at 6 weeks relative to the sham group. PMID 21337043 ↗

paper However, the visual improvements in the IVB group were not significantly different from those in the sham group at 12 weeks. PMID 21337043 ↗

Publications

Moradian S, Faghihi H, Sadeghi B, Piri N, Ahmadieh H, Soheilian M, Dehghan MH, Azarmina M, Esfahani MR. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):193-200. doi: 10.1007/s00417-010-1440-8. Epub 2010 Aug 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	125 mg	Intravitreal